Summary & Overview
HCPCS Level II J3030: Sumatriptan Succinate Injection, 6 mg
HCPCS Level II code J3030 denotes a 6 mg injection of sumatriptan succinate administered under direct physician supervision. Nationally, this code is used to bill for injectable migraine treatment provided in supervised outpatient settings such as physician offices or infusion suites. The code matters because it differentiates clinician-administered therapy from self-administered prescriptions, affecting coverage, site-of-service policies, and billing workflows across payers.
Key payers included in this analysis are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of payer coverage considerations, billing and site-of-service implications, and clinical context for use of parenteral sumatriptan in acute migraine management. The publication also summarizes common modifiers and administrative details relevant to claims processing; where specific payer policy details are not provided, the text will note that input data did not include them.
This resource is intended to help billing professionals, clinicians, and policy analysts understand when J3030 applies, typical delivery settings, and the distinctions that affect reimbursement and utilization tracking for injectable migraine therapy.
Billing Code Overview
HCPCS Level II code J3030 represents an injection of sumatriptan succinate, 6 mg administered by a clinician. The code is intended for situations where the drug is administered under the direct supervision of a physician and is not used for self-administered injections.
Service Type: Parenteral medication administration (injectable migraine therapy)
Typical Site of Service: Clinic or physician office setting where injectable medications are given under direct medical supervision.
Data not available in the input for associated taxonomies, ICD-10 diagnoses, related codes, or service line.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult presenting to an outpatient neurology clinic or an emergency department with an acute moderate-to-severe migraine attack unresponsive to oral therapies. The clinician evaluates the patient, documents migraine history, current attack characteristics (onset, severity, associated nausea/photophobia), and confirms no contraindications to triptan therapy (eg, ischemic heart disease, uncontrolled hypertension). Under direct physician supervision, an intramuscular or subcutaneous injection of sumatriptan succinate 6 mg (J3030) is prepared and administered by a licensed clinician or nurse. Vital signs are monitored before and after administration, adverse effects (chest pressure, paresthesia, dizziness) are documented, and disposition is determined (discharge with headache plan or observation). For Medicare billing, J3030 is used when the medication is administered in a clinical setting and not self-administered by the patient.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
23 | Unusual Anesthesia | Use when unexpected anesthesia is provided for a procedure related to acute pain management during injection (rare for J3030). |